Twitter summary: There is a small risk of cross infection with Pseudomonas aeruginosa in bronchiectasis, but the benefit of specialised clinics, chest physiotherapy and pulmonary rehabilitation outweigh theoretical risks.
The risk of cross-infection with pathogens such as Pseudomonas aeruginosa, Methicillin Resistant
Staphylococcus aureus (MRSA) and Burkholderia cepacia complex, and most recently Mycobacterium abscessus is a matter of considerable concern in patients with cystic fibrosis bronchiectasis (CF). (1) (2) (3) (4) As a result of compelling evidence of transmission of these organisms between people with CF and, in the case of P. aeruginosa, the identification of transmissible "epidemic" strains, clear guidance and restrictions on contact between CF patients have been introduced.(5,6) CF clinics are segregated, with separate clinics for patients with B. cepacia complex infection, P. aeruginosa and other infections.
Within clinics, any direct contact between individuals with CF is avoided. In hospital wards, patients in most countries will be kept in side rooms separated from other patients, or may be kept on separate wards if patients with different infections are hospitalised concurrently. (5, 6) CF physicians are also advised to practice rigorous hand hygiene and other measures since microorganisms can survive on surfaces, hands or clothing for several hours. (4, 7) For patient support events and conferences, participation by CF patients is heavily restricted. The CF Trust in the UK limits participation strictly to a single CF patient for indoor events and has strict regulations for outdoor events. Virtually all international guidelines for CF advocate similar measures to reduce the risk of cross-infection. (5, 6) P. aeruginosa transmission is also a potential concern in bronchiectasis not due to CF (henceforth referred to as bronchiectasis) because of evidence that P. aeruginosa infection is associated with an increased risk of death, exacerbation and worse quality of life. (8) The European Respiratory Society (ERS) guidelines for bronchiectasis, published in the European Respiratory Journal in September 2017, did not address the issue of cross-infection. (9) This reflects the lack of evidence, which prevents recommendations being made in a GRADE based guideline. Of note, the current Spanish Society of Pneumology and Thoracic Surgery (SEPAR), the British Thoracic Society and the guidelines from Australia and New Zealand also make no specific recommendations regarding the risk of cross-infection. (10) (11) (12) The ERS guidelines do, however, emphasise the importance of specialised care for the management of bronchiectasis, which is best delivered within specialised centres seeing a large number of patients. (9, (13) (14) (15) The ERS guidelines recommend that patients with bronchiectasis and significant breathlessness attend pulmonary rehabilitation.(9) Pulmonary rehabilitation and specialist outpatient clinics are two environments where patients with bronchiectasis will inevitably come into contact with other patients.
Bronchiectasis has been a neglected condition. (13) This has led, in part, to the development of strong patient led advocacy groups. These groups have been a major benefit to the field, aiding in the development of clinical guidelines, priority setting, peer support and education. 
What is the evidence for the risk of cross-infection in bronchiectasis?
Bronchiectasis and CF are two quite distinct conditions, with a different spectrum of microbiology and a different pathophysiology.(17) B. cepacia complex, the most feared transmissible pathogens in CF, is very rarely cultured in bronchiectasis. (14-18) While P. aeruginosa is almost universal in CF over a patient's lifetime, P. aeruginosa affects only 20% of patients with bronchiectasis in Europe. (8, 15, 17, 19) .
It may be speculated that only a proportion of patients with bronchiectasis are susceptible to persistent P. aeruginosa infection which tends to be concentrated in patients with more severe and extensive bronchiectasis. (20) We conducted a systematic review using Pubmed (using search terms "cross-infection" OR 2-There is insufficient evidence to show that cross-infection is associated with clinical deterioration.
3-Epidemic and highly transmissible strains have not been identified in the bronchiectasis
population, except in one study where these were shown to be likely acquired from CF patients.
4-
The strongest evidence for transmission overall and transmission of multidrug resistant or highly virulent strains in particular appears to be from CF patients to bronchiectasis patients, rather than within the bronchiectasis population. EMBARC data suggests that 10% of bronchiectasis patients in Europe are managed in CF clinics, while 45% are managed in centres with shared facilities for CF patients. and an acceptable risk if the alternative is a lack of availability of peer support, specialised clinics and services such as pulmonary rehabilitation which currently require patients to be together. The majority of patients thought they had a right to know about the risks so that they could make an informed decision about, for example, attending patient support group events. Many patients expressed concern that their condition would be stigmatised if they are required to wear masks or are unable to be in contact with others. In general, patients expressed frustration that infection control measures are often neglected in terms of their general management. Exacerbations resulting from exposure to relatives, members of the public or other patients with viral infections is a more frequent and regular problem for patients, and measures to avoid acquiring such infections are rarely discussed with patients.
Recommendations
Where Bronchiectasis patients are managed within a CF service we suggest managing these patients Within bronchiectasis clinics, a balance must be found between the theoretical risk of cross-infection, and the risk of adversely impacting patient care. Patients with bronchiectasis benefit from specialist care in centres that see a large number of patients. Cohorting patients by organism is likely to be impractical in many hospitals in the absence of specific funding for this. Cohorting is also difficult to justify since our review did not identify a single confirmed case of new infection with P. aeruginosa acquired from a fellow patient with bronchiectasis. It is our judgement that there is currently not sufficient evidence to recommend separation of bronchiectasis patients with P. aeruginosa infection. Similarly, there are clear benefits of pulmonary rehabilitation with the evidence demonstrating improved exercise capacity, improved quality of life and reduced exacerbations.(9) These benefits outweigh the theoretical risk that attending a pulmonary rehabilitation class with other patients could expose the patient to the risk of transmission of a microorganism. Again, there is no evidence that pulmonary rehabilitation related transmission has occurred. Care for bronchiectasis in Europe is currently heterogeneous and predominantly inadequate with data suggesting most patients do not receive what may be regarded as the basic components of bronchiectasis care, such as access to chest physiotherapy, sputum culture, antibiotic therapy and self-management. (29) In this context, precious resources should be directed at improving basic medical management.
Nevertheless, we suggest that patients with specific multi-drug and pan-drug resistant pathogens including M. abscessus and MRSA should be managed according to strict infection control procedures in the outpatient and inpatient setting. For all patients, care should be taken with aerosol generating procedures and we suggest that procedures such as sputum induction, chest physiotherapy or spirometry should be performed in separate and well ventilated rooms.
In the event of suspected transmission or a suspected outbreak we recommend seeking expert microbiological help. Facilities to investigate potential outbreaks using molecular methods should be made available.
We recommend that discussing the topic of infection control, including avoiding infections as well as the risk of transmission should be part of the bronchiectasis clinic consultation for all patients.
For patient support groups, research initiatives and social events, the balance of risks and benefits must be carefully weighed on a case-by-case basis. The value to patients of participation in such events is clear, and the need for advocacy and support in a disease like bronchiectasis is acute. Therefore, in the absence of evidence of harm, we do not currently advocate preventing patients from participating in such activities. We nevertheless make the following recommendations:
 Patients should be informed that contact with other patients may carry a risk of transmission of infection. This allows patients to make an informed decision about whether to participate in such events.
 All participants at such events should practice rigorous hand hygiene measures. Patients should aim to minimise aerosols e.g. conduct chest clearance at home prior to attending and at events and cover their mouth while coughing.
 Since shaking of hands is known to be a primary source of pathogen transmission in other areas, hand shaking at events is discouraged.  We suggest that specific groups of patients are at higher risk from cross-infection e.g immunocompromised patients, or those with multidrug resistant organisms should discuss with their physician prior to attending events.  Where electronic or virtual means of communication (teleconferences, webinars etc) can be used, they should be used.
Patients are also concerned to reduce their risk of exacerbation by reducing the acquisition of viral and other infections from patients. We identified no evidence that infection control measures can prevent exacerbations. We therefore suggest that patients are advised to practice standard hygiene measures, such as hand washing before meals and that patients should avoid contact where possible with children and adults with active viral infections. It was discussed that some patients in online forums recommend face-masks to reduce infection risk in bronchiectasis. The panel recommended against the use of facemasks due to a lack of evidence for their effectiveness and the risk of stigmatising bronchiectasis patients.
Finally, the topic of cross-infection is a key research priority in bronchiectasis. Cross-infection was identified by both patients and physicians as one of the 55 key research questions in the field of bronchiectasis, In the EMBARC "roadmap" published in 2016. (17) We strongly recommend that large scale longitudinal studies are performed to ascertain the incidence and clinical implications of crossinfection in bronchiectasis.
